![PDF) Effectiveness and Safety of the Switch from Remicade® to CT-P13 in Patients with Inflammatory Bowel Disease PDF) Effectiveness and Safety of the Switch from Remicade® to CT-P13 in Patients with Inflammatory Bowel Disease](https://i1.rgstatic.net/publication/336924231_Effectiveness_and_Safety_of_the_Switch_from_RemicadeR_to_CT-P13_in_Patients_with_Inflammatory_Bowel_Disease/links/60c086aea6fdcc512816e3e9/largepreview.png)
PDF) Effectiveness and Safety of the Switch from Remicade® to CT-P13 in Patients with Inflammatory Bowel Disease
![PDF) Systemic Molecular Mediators of Inflammation Differentiate Between Crohn's Disease and Ulcerative Colitis, Implicating Threshold Levels of IL-10 and Relative Ratios of Pro-inflammatory Cytokines in Therapy PDF) Systemic Molecular Mediators of Inflammation Differentiate Between Crohn's Disease and Ulcerative Colitis, Implicating Threshold Levels of IL-10 and Relative Ratios of Pro-inflammatory Cytokines in Therapy](https://i1.rgstatic.net/publication/334065147_Systemic_Molecular_Mediators_of_Inflammation_Differentiate_Between_Crohn's_Disease_and_Ulcerative_Colitis_Implicating_Threshold_Levels_of_IL-10_and_Relative_Ratios_of_Pro-inflammatory_Cytokines_in_The/links/5ef6476a92851c52d6febd47/largepreview.png)
PDF) Systemic Molecular Mediators of Inflammation Differentiate Between Crohn's Disease and Ulcerative Colitis, Implicating Threshold Levels of IL-10 and Relative Ratios of Pro-inflammatory Cytokines in Therapy
![PDF) Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort PDF) Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort](https://i1.rgstatic.net/publication/331136458_Real-world_Effectiveness_and_Safety_of_Vedolizumab_for_the_Treatment_of_Inflammatory_Bowel_Disease_The_Scottish_Vedolizumab_Cohort/links/5ede5476299bf1d20bd8f397/largepreview.png)
PDF) Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort
![European Crohn's and Colitis Organisation (ECCO) Congress 2019, Bella Center, Copenhagen, Copenhagen (Hovedstaden), Denmark | eMedEvents European Crohn's and Colitis Organisation (ECCO) Congress 2019, Bella Center, Copenhagen, Copenhagen (Hovedstaden), Denmark | eMedEvents](https://d3p2qewzsoh75c.cloudfront.net/uploads/conferences/logo/200/european_crohn_s_and_colitis_organisation_ecco_1538201630.jpeg)
European Crohn's and Colitis Organisation (ECCO) Congress 2019, Bella Center, Copenhagen, Copenhagen (Hovedstaden), Denmark | eMedEvents
![ECCO update on COVID-19 and IBD | International Organization For the Study of Inflammatory Bowel Disease ECCO update on COVID-19 and IBD | International Organization For the Study of Inflammatory Bowel Disease](https://ioibd.org/wp-content/uploads/2020/04/news-ecco-1080x675.jpg)
ECCO update on COVID-19 and IBD | International Organization For the Study of Inflammatory Bowel Disease
![COVID-19 and IBD: Guidance from IOIBD and ECCO on management of patients | International Organization For the Study of Inflammatory Bowel Disease COVID-19 and IBD: Guidance from IOIBD and ECCO on management of patients | International Organization For the Study of Inflammatory Bowel Disease](https://ioibd.org/wp-content/uploads/2020/11/front_matter-JCC-Journal-pdf.jpg)
COVID-19 and IBD: Guidance from IOIBD and ECCO on management of patients | International Organization For the Study of Inflammatory Bowel Disease
![PDF) Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies PDF) Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies](https://i1.rgstatic.net/publication/333445914_Efficacy_and_Safety_of_Adalimumab_by_Disease_Duration_Analysis_of_Pooled_Data_From_Crohn's_Disease_Studies/links/5cf1cd6c4585153c3daa27a3/largepreview.png)